 REDWOOD CITY, Calif.--BUSINESS WIRE--Guardant Health, Inc. Nasdaq: GH has CE-marked Guardant360 CDx for tumor mutation profiling, also known as comprehensive genomic profiling CGP, in patients with any solid malignant neoplasm cancerous tumor. The test is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor EGFR alterations who may benefit from treatment with Tagrisso osimertinib. The Guardant360 CDx test off 